Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cara Therapeutics (CARA US)

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Current Report (Amendment) (Form 8-K/A | Period ending 2024-12-17)

S-4 | Registration of securities issued in business combination transactions

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Current Report (Form 8-K | Period ending 2024-12-17)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)